Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis
R. Schelbergen(Radboud University Medical Center), Peter L. E. M. van Lent(Radboud University Nijmegen), Thomas Vogl(Goethe University Frankfurt), E.J. Geven(Radboud University Nijmegen), Fons A. J. van de Loo(Radboud University Nijmegen), Arjen B. Blom(Radboud University Nijmegen), Tomas Leanderson(Lund University), Johannes Roth(University of Münster), Martijn H. J. van den Bosch(Radboud University Nijmegen), P.M. van der Kraan(Radboud University Nijmegen), Wim B. van den Berg(Radboud University Nijmegen), Helena Eriksson(Active Biotech (Sweden)), Marije I. Koenders(Radboud University Nijmegen)
Cited by 93
Related Papers
Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock
|Nature Immunology|2003|363
Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides
|PLoS Biology|2009|358
Increase in ALK1/ALK5 Ratio as a Cause for Elevated MMP-13 Expression in Osteoarthritis in Humans and Mice
|The Journal of Immunology|2009|315
Blocking of Interleukin-17 during Reactivation of Experimental Arthritis Prevents Joint Inflammation and Bone Erosion by Decreasing RANKL and Interleukin-1
|American Journal Of Pathology|2005|306
Type I IFN Signaling Is Crucial for Host Resistance against Different Species of Pathogenic Bacteria
|The Journal of Immunology|2007|246